This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Tositumomab and Iodine-131 Tositumomab
Description: Like Rituxan and Zevalin, Bexxar binds to the CD20 protein on the surface of B cells and B cell tumors. The ability of Bexxar to kill target cells is increased by the conjugation of radioactive iodine to the monoclonal antibody. Zevalin, also a radioactive monoclonal antibody, uses yttrium instead of iodine, while Rituxan is unconjugated.
Deal Structure: Bexxar was developed by Coulter, which was later acquired by Corixa.
In December 1998, Coulter and SmithKline Beecham (SB) entered into a collaborative agreement for the development and commercialization of Bexxar. Under the terms of the agreement, Coulter may receive milestone payments, shared profits and royalties. The agreement also provides for the sharing of certain costs related to clinical development, manufacturing development, and sales & marketing costs. Coulter and SB will prepare a joint profit & loss statement to account for the sharing of sales, cost of goods sold, and costs related to selling, marketing, distribution and certain other Bexxar-related activities. The agreement provides for an upfront non-refundable license fee of $34.25 million and the purchase of $7.25 million of Coulter's common stock. Coulter may receive additional payments based upon completion of certain milestones. Future development expenses for Bexxar will generally be shared by both...See full deal structure in Biomedtracker
Additional information available to subscribers only: